Patents by Inventor Yasuko Nakagawa
Yasuko Nakagawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9994816Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.Type: GrantFiled: May 4, 2015Date of Patent: June 12, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yuichi Ono, Toshio Imai, Yasuko Nakagawa
-
Publication number: 20150299654Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.Type: ApplicationFiled: May 4, 2015Publication date: October 22, 2015Inventors: Yoshimasa Sakamoto, Yuichi Ono, Toshio Imai, Yasuko Nakagawa
-
Patent number: 8877449Abstract: The present invention provides markers that can selectively distinguish pancreatic progenitor cells. The present invention also provides methods for distinguishing pancreatic progenitor cells by using the markers as an indicator, and reagents to be used in the methods. The present inventors successfully identified the surface marker Nephrin-like 3 (Neph3) which is specifically expressed in pancreatic progenitor cells, and isolated pancreatic progenitor cells using the marker as an indicator or such. Viable pancreatic progenitor cells can be selected by using Neph3 as an indicator without using translated products and transcripts of any foreign genes. The marker is useful in preparing and identifying pancreatic progenitor cells which are applied to regenerative medicine or such for treatment of pancreatic diseases.Type: GrantFiled: December 18, 2009Date of Patent: November 4, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Tomoya Nakatani, Yasuko Nakagawa
-
Patent number: 8609405Abstract: The present inventors identified a selective marker 65B13 for GABA neuron progenitor cells of the spinal dorsal horn and cerebellum, and successfully isolated GABA neuron progenitor cells using antibodies that bind to a protein encoded by the gene. 65B13 was demonstrated to be useful as a marker to isolate GABA-producing neuron progenitor cells in the spinal dorsal horn and cerebellum. GABA neuron progenitor cells can be efficiently identified or isolated by using the identified marker as an indicator.Type: GrantFiled: February 7, 2008Date of Patent: December 17, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Eri Mizuhara
-
Patent number: 8580523Abstract: The present invention identified Lmx1a genes, which are expressed in dopaminergic neurons at all differentiation stages, from proliferating dopaminergic neuron progenitor cells before cell cycle exit to cells after cell cycle exit. Lmx1a expression in cells can be used as an indicator when selecting cells suitable for transplantation therapy for neurodegenerative diseases such as Parkinson's disease, and is useful as a marker for screening agents involved in the induction of dopaminergic neuron differentiation.Type: GrantFiled: January 17, 2012Date of Patent: November 12, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani
-
Patent number: 8232052Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: GrantFiled: August 25, 2010Date of Patent: July 31, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Publication number: 20120178083Abstract: The present invention identified Lmx1a genes, which are expressed in dopaminergic neurons at all differentiation stages, from proliferating dopaminergic neuron progenitor cells before cell cycle exit to cells after cell cycle exit. Lmx1a expression in cells can be used as an indicator when selecting cells suitable for transplantation therapy for neurodegenerative diseases such as Parkinson's disease, and is useful as a marker for screening agents involved in the induction of dopaminergic neuron differentiation.Type: ApplicationFiled: January 17, 2012Publication date: July 12, 2012Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani
-
Patent number: 8187804Abstract: The present invention identified Lmx1a genes, which are expressed in dopaminergic neurons at all differentiation stages, from proliferating dopaminergic neuron progenitor cells before cell cycle exit to cells after cell cycle exit. Lmx1a expression in cells can be used as an indicator when selecting cells suitable for transplantation therapy for neurodegenerative diseases such as Parkinson's disease, and is useful as a marker for screening agents involved in the induction of dopaminergic neuron differentiation.Type: GrantFiled: November 26, 2004Date of Patent: May 29, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani
-
Publication number: 20120021417Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: September 29, 2011Publication date: January 26, 2012Applicant: EISAI R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Patent number: 8067161Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: GrantFiled: August 18, 2006Date of Patent: November 29, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Publication number: 20110256548Abstract: The present invention provides markers that can selectively distinguish pancreatic progenitor cells. The present invention also provides methods for distinguishing pancreatic progenitor cells by using the markers as an indicator, and reagents to be used in the methods. The present inventors successfully identified the surface marker Nephrin-like 3 (Neph3) which is specifically expressed in pancreatic progenitor cells, and isolated pancreatic progenitor cells using the marker as an indicator or such. Viable pancreatic progenitor cells can be selected by using Neph3 as an indicator without using translated products and transcripts of any foreign genes. The marker is useful in preparing and identifying pancreatic progenitor cells which are applied to regenerative medicine or such for treatment of pancreatic diseases.Type: ApplicationFiled: December 18, 2009Publication date: October 20, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Tomoya Nakatani, Yasuko Nakagawa
-
Patent number: 8039224Abstract: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.Type: GrantFiled: October 8, 2009Date of Patent: October 18, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Yasuko Nakagawa, Yuichi Ono, Yoshimasa Sakamoto, Eri Mizuhara, Tomoya Nakatani, Yoshimi Takai
-
Publication number: 20110229889Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: March 24, 2011Publication date: September 22, 2011Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Publication number: 20110201003Abstract: 65B13 was discovered to be a useful marker for isolating GABA neuron progenitor cells including Purkinje cells. Furthermore, E-cadherin was revealed to be a useful marker for isolating Purkinje progenitor cells from a 65B13-positive cell population. Specifically, when used in combination with 65B13, E-cadherin was found to be a useful marker for isolating Purkinje progenitor cells.Type: ApplicationFiled: August 6, 2009Publication date: August 18, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Eri Mizuhara
-
Publication number: 20100323366Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: ApplicationFiled: August 25, 2010Publication date: December 23, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Publication number: 20100303771Abstract: The present inventors identified a selective marker 65B13 for GABA neuron progenitor cells of the spinal dorsal horn and cerebellum, and successfully isolated GABA neuron progenitor cells using antibodies that bind to a protein encoded by the gene. 65B13 was demonstrated to be useful as a marker to isolate GABA-producing neuron progenitor cells in the spinal dorsal horn and cerebellum. GABA neuron progenitor cells can be efficiently identified or isolated by using the identified marker as an indicator.Type: ApplicationFiled: February 7, 2008Publication date: December 2, 2010Applicant: Eisai R & D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Eri Mizuhara
-
Patent number: 7807371Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: GrantFiled: April 25, 2008Date of Patent: October 5, 2010Assignee: Eisai R & D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Publication number: 20100203570Abstract: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.Type: ApplicationFiled: October 8, 2009Publication date: August 12, 2010Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yasuko Nakagawa, Yuichi Ono, Yoshimasa Sakamoto, Eri Mizuhara, Tomoya Nakatani, Yoshimi Takai
-
Publication number: 20100203505Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: August 18, 2006Publication date: August 12, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Publication number: 20100028866Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: August 18, 2006Publication date: February 4, 2010Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto